The De Novo process provides a pathway to classify novel medical devices for which general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, but for which there is no legally marketed predicate device. De Novo classification is a risk-based classification process.
Devices that are classified into class I or class II through a De Novo classification request may be marketed and used as predicates for future premarket notification [510(k)] submissions.
|Eonis SCID-SMA Kit||2022-11-09|
|INNOVANCE VWF Ac||2022-09-29|
|APOLLO ESG System, APOLLO ESG SX System, APOLLO REVISE System, APOLLO REVISE SX System||2022-07-12|
|BioFire Joint Infection (JI) Panel||2022-04-29|